Skip to main content
Caplight Logo









AquaNab Solutions

AquaNab Solutions

Private
HamburgHealthcare & Life Scienceshttps://aquanabs.de/

Last Round

Early Funding

Aug 11, 2026

Momentum

Top 25%

of companies Caplight tracks

Company Overview

AquaNab Solutions is a biotechnology company that develops alpaca-derived nano-antibody therapeutics to control pathogenic infections in farmed salmon.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

nanoantibodyaquacultureimmunotherapeuticsfish healthsalmon farmingfeed-delivered therapeuticsbiotech startuppathogen controlalpaca antibodiesnanobodyaquaculture techanimal healthsustainable aquaculturedrug discoveryagtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AquaNab Solutions Comparables

Compare AquaNab Solutions with similar companies based on industry and business-model similarity.

AquaNab Solutions comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Sundew Bio
77%
ViAqua Therapeutics
76%
FeedVax
76%

AquaNab Solutions Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingAug 11, 2026

AquaNab Solutions Investors

Notable investors and investment history

AquaNab Solutions investors
InvestorRounds
Nordic Foodtech VCEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 11, 2026

    Nordic Foodtech VC led the early funding round.

Recent news

Latest coverage and updates

  • is_developingAug 11, 2026

    AquaNabs is developing precision nanoantibody technology that delivers alpaca-derived nanoantibodies through fish feed. on Aug 11th '26.

  • is_developingAug 11, 2026

    AquaNabs is developing precision immunotherapies for aquaculture on Aug 11th '26.

AquaNab Solutions Filings

Explore SEC and related filing metadata, where available.

AquaNab Solutions filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about AquaNab Solutions's valuation, stock price, and market status.

Is AquaNab Solutions a public or private company?

AquaNab Solutions is a private company.

What is the current stock price of AquaNab Solutions?

AquaNab Solutions is a private company with no public stock price. Caplight tracks AquaNab Solutions's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is AquaNab Solutions worth (valuation)?

Valuation information for AquaNab Solutions is not publicly available.

Can I buy AquaNab Solutions stock?

AquaNab Solutions shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was AquaNab Solutions's last funding round?

AquaNab Solutions's most recent funding round was Early Funding on August 11, 2026.

Who are the main investors in AquaNab Solutions?

Key investors in AquaNab Solutions include Nordic Foodtech VC.

Will AquaNab Solutions IPO soon?

No public IPO plans have been announced for AquaNab Solutions.

How can I track AquaNab Solutions secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AquaNab Solutions's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHamburg
Year Founded2023
Last FundingAug 11, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?